World Sleep Industry ENCYCLOPEDIA

OTC melatonin preparations

2.1.2

Name, ingredient, and regulatory status

Melatonin is an indoleamine signal produced mainly during the biological night; exogenous melatonin is a finished preparation administered in milligrams or another stated unit. This entry is indexed under WSIC 2.1.2 and covers products obtainable without an ordinary prescription and marketed for sleep or circadian purposes. “Natural,” “identical to a human hormone,” or shelf availability does not mean that every lot's content, indication, and risks received medicine-level premarket review.

“OTC preparation” is not one global legal category. In the United States, marketed melatonin is generally a dietary supplement and is not an active ingredient in the OTC nighttime sleep-aid monograph. It is ordinarily prescription-only in the United Kingdom; the European Union has prescription prolonged-release products for defined ages and indications; and Australia permits pharmacist supply of only certain products under restricted conditions. Purchase, import, carriage, and use must follow the local rules and exact label rather than a shelf status imported from another country.

Biological timing and formulation differences

Exogenous melatonin may produce pre-sleep drowsiness and may advance or delay the biological clock according to the phase at which it is taken. Effects depend on endogenous phase, light exposure, timing, dose, and the individual—not on a simple rule that more milligrams create more “night.” Administration at an unsuitable phase may have little effect or shift rhythms in an unintended direction. One clock time should not be presented as a universal answer without assessing schedule, a sleep diary, and light history.

Immediate-release tablets, prolonged- or controlled-release tablets, gummies, liquids, sprays, sublingual forms, and combination products differ in release profile, absorption, and excipients; equal labelled amounts are not automatically interchangeable. Immediate release is associated with a relatively rapid concentration peak, while prolonged release is designed to extend delivery, but the dosage-form name alone does not guarantee a particular sleep outcome. Whether a prolonged-release tablet may be split or chewed, the proper liquid measure, the amount per spray, and the relationship to food must follow that finished product's instructions.

Target problems and evidence boundary

“Poor sleep” can mean occasional sleep-onset difficulty, chronic insomnia, jet lag, delayed sleep-wake phase disorder, or a shift-work-related problem. These are not one diagnosis. In selected circadian disorders, a deliberately timed melatonin plan can be a treatment component; some jurisdictions also authorize a defined prolonged-release medicine for short-term primary insomnia in adults of a specified age. Such evidence does not transfer automatically to any gummy, any dose, or every person with insomnia.

The American Academy of Sleep Medicine made a weak recommendation against melatonin for chronic sleep-onset or sleep-maintenance insomnia in adults, reflecting the effects and limitations of the evidence then available rather than claiming that no user ever feels an effect. Multicomponent cognitive behavioral therapy for insomnia is first-line treatment for chronic insomnia. Advertising terms such as “deep sleep,” “all night,” or “reset,” and a single-night wearable score, cannot replace evaluation of duration, daytime function, reliable sleep outcomes, and adverse events.

Label, content, and product checks

Read the full label rather than the front panel. Confirm the melatonin amount per serving—not merely per tablet or gummy—the number of units in a serving, all other active ingredients, sugars or sugar alcohols, allergens, lot, expiry, storage, and manufacturer information. Magnesium, valerian, theanine, antihistamines, botanicals, or cannabinoids in a combination have separate evidence and risks. A combination's effects cannot all be attributed to melatonin, and multiple products marketed for sleep should not be stacked.

Sampling studies of Canadian melatonin supplements and United States melatonin gummies found substantial differences between measured and labelled content; some samples lacked detectable labelled melatonin, and some contained undeclared or combined ingredients. These findings demonstrate possible market and lot quality problems, not that every product is defective. A traceable lot, a disclosed testing scope, and credible independent certification can inform selection. Third-party verification establishes only what was actually tested or certified; it is not proof of clinical benefit, suitability for one person, or regulatory endorsement.

Use, records, and next-day function

If a trial is consistent with local labelling and professional judgment, change only one factor at a time, use the accurate measuring device or complete dosage unit, and record administration time, lights-out, sleep onset, awakenings, rise time, morning state, and unusual effects. Do not add repeated amounts because sleepiness was not felt that evening, and do not use one formulation to top up another. Pay particular attention after first use or a change of lot or formulation. Ongoing reliance, diminishing effect, or recurrent insomnia calls for diagnostic and medication review rather than continued self-experimentation.

Melatonin can cause somnolence, dizziness, headache, nausea, and altered dreams, and next-day residual effects vary. Until fully alert after use, a person should not drive, cycle, climb, operate machinery, or perform work requiring rapid judgment; coffee and feeling subjectively normal do not establish unimpaired performance. Those at increased risk of a nighttime fall should address lighting and route safety. Syncope, severe allergy, marked alteration of consciousness, or another emergency sign requires prompt help.

Interactions and priority populations

Alcohol and sedative-hypnotics, opioids, sedating antihistamines, and similar agents can add to drowsiness and functional impairment. Fluvoxamine and other CYP1A2 modifiers may substantially alter exposure, while smoking and some enzyme inducers may change effects. Anticoagulants, antiseizure medicines, immunosuppressive treatment, and complex polypharmacy warrant professional reconciliation. The relevant interaction list varies by preparation and patient and cannot be neutralized reliably by self-selected spacing of a few hours.

Pregnancy or breastfeeding, hepatic or renal impairment, autoimmune disease, epilepsy, bleeding risk, planned surgery, increased fall risk in older age, and cancer or immune treatment require prior professional review of evidence, risks, and alternatives. Approval of a particular prescription melatonin medicine for one population does not give a shelf supplement the same quality, release characteristics, or indication. Nor does its identity as an endogenous hormone establish that prolonged, high-amount, or combination use is inherently safe.

Child safety and sleep-medicine boundaries

Use in a child should first be discussed by a parent or caregiver with a pediatric professional, with attention to schedule, light, behavior, breathing, and neurodevelopmental causes. Some prescription prolonged-release products are limited to selected children with particular neurodevelopmental disorders after sleep-hygiene measures have been insufficient; that indication cannot be generalized to all children. Pediatric randomized studies suggest more non-serious adverse events, while long-term growth, pubertal, and generally healthy-child evidence remains limited. A gummy must not be treated as food, a reward, or unsupervised long-term maintenance.

The appearance and taste of gummies increase the risk of unintended ingestion. Keep every preparation in its original, tightly closed container, locked and out of children's sight and reach; visitor bags, bedside drawers, and travel organizers also require control. A child's ingestion, an uncertain amount, unusual somnolence, repeated vomiting, breathing difficulty, a seizure, or inability to awaken requires immediate contact with the local poison-information or emergency service, with the package available; do not wait for the child to “sleep it off.” Persistent insomnia, loud snoring, witnessed breathing pauses, abnormal sleep behavior, or substantial daytime problems require appropriate sleep assessment rather than escalating melatonin.